Women with early-stage breast cancer who couldn't enter clinical trials of cryoablation because of "unfavorable" tumor or patient characteristics nevertheless enjoyed a high rate of treatment success ...

The FDA granted marketing authorization for the ProSense Cryoablation System for small, early-stage breast cancer in older women not suitable for surgery, maker IceCure announced. A minimally invasive ...

While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires ...

Cryoablation (also called cryosurgery or cryotherapy) uses very low temperatures to freeze abnormal tissue, destroying it during freezing. A medical professional uses a cryoprobe, which is cooled with ...

Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized small renal masses, supporting its role as a surgery-sparing local ...

The IceCure-sponsored symposium featured leading breast surgeons and cryoablation users, including Richard Fine, M.D., breast oncology surgeon at West Cancer Center & Research Institute, Michael Sabel ...

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . Patients who received cryoablation as treatment for breast cancer had low recurrence rate after 16 months.

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...

CAESAREA, Israel, March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...

ASBrS's updated "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" is pending finalization following the end of its ...